Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin

Journal of Virology

Volumn 90, Issue 1, 2016, Pages 332-344

  Brazzoli, Michela ^a,e   Magini, Diletta ^a,b,e   Bonci, Alessandra ^a,e   Buccato, Scilla ^a,e   Giovani, Cinzia ^a,e   Kratzer, Roland ^a,f   Zurli, Vanessa ^a,c,e   Mangiavacchi, Simona ^a,e   Casini, Daniele ^a,e   Brito, Luis M ^d,g   Gregorio, Ennio De ^a,e   Mason, Peter W ^d,h   Ulmer, Jeffrey B ^d,i   Geall, Andrew J ^d,j   Bertholet, Sylvie ^a,e  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d Novartis Vaccines and Diagnostic   (United States)

^e GSK   (Italy)

^f TRANSGENE S A   (France)

^g MODERNA THERAPEUTICS   (United States)

^h REGENERON PHARMACEUTICALS INC   (United States)

ⁱ GLAXOSMITHKLINE   (United States)

^j Avidity NanoMedicines   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; MESSENGER RNA VACCINE; RNA VACCINE; UNCLASSIFIED DRUG; DNA VACCINE; INFLUENZA VACCINE; MESSENGER RNA; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOREACTIVITY; LYMPHOCYTE DEPLETION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SEASONAL INFLUENZA; VIRUS LOAD; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CROSS PROTECTION; DISEASE MODEL; FERRET; GENETICS; IMMUNOLOGY; LEUKAPHERESIS; METABOLISM; ORTHOMYXOVIRIDAE INFECTIONS; RESPIRATORY SYSTEM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS PROTECTION; DISEASE MODELS, ANIMAL; FEMALE; FERRETS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA VACCINES; LEUKOCYTE REDUCTION PROCEDURES; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RESPIRATORY SYSTEM; RNA, MESSENGER; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINES, DNA; VIRAL LOAD;

EID: 84953851839     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01786-15     Document Type: Article

References (82)

1. Tu W, Mao H, Zheng J, Liu Y, Chiu SS, Qin G, Chan PL, Lam KT, Guan J, Zhang L, Guan Y, Yuen KY, Peiris JS, Lau YL. 2010. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol 84:6527-6535. http://dx.doi.org/10.1128/JVI.00519-10.
2. Alam S, Sant AJ. 2011. Infection with seasonal influenza virus elicits CD4 T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza virus. J Virol 85:13310-13321. http://dx.doi.org/10.1128/JVI.05728-11.
3. Chen GL, Lau YF, Lamirande EW, McCall AW, Subbarao K. 2011. Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine. Proc Natl Acad Sci U S A 108:1140-1145. http://dx.doi.org/10.1073/pnas.1009908108.
4. Guo H, Santiago F, Lambert K, Takimoto T, Topham DJ. 2011. T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model. J Virol 85:448-455. http://dx.doi.org/10.1128/JVI.01812-10.
5. Hillaire ML, van Trierum SE, Kreijtz JH, Bodewes R, Geelhoed-Mieras MM, Nieuwkoop NJ, Fouchier RA, Kuiken T, Osterhaus AD, Rimmelzwaan GF. 2011. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T cells. J Gen Virol 92:2339-2349. http://dx.doi.org/10.1099/vir.0.033076-0.
6. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. 2003. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol 115:63-73.
7. Rimmelzwaan GF, McElhaney JE. 2008. Correlates of protection: novel generations of influenza vaccines. Vaccine 26(Suppl 4):D41-D44. http://dx.doi.org/10.1016/j.vaccine.2008.07.043.
8. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. 2011. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccineinduced protection. J Infect Dis 204:1879-1885. http://dx.doi.org/10.1093/infdis/jir661.
9. Tosh PK, Boyce TG, Poland GA. 2008. Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clinic Proc 83:77-84. http://dx.doi.org/10.4065/83.1.77.
10. Tomoda T, Morita H, Kurashige T, Maassab HF. 1995. Prevention of influenza by the intranasal administration of cold-recombinant, liveattenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response. Vaccine 13:185-190. http://dx.doi.org/10.1016/0264-410X(95)93134-U.
11. Gorse GJ, Campbell MJ, Otto EE, Powers DC, Chambers GW, Newman FK. 1995. Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine. J Infect Dis 172:1-10. http://dx.doi.org/10.1093/infdis/172.1.1.
12. Powell TJ, Strutt T, Reome J, Hollenbaugh JA, Roberts AD, Woodland DL, Swain SL, Dutton RW. 2007. Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J Immunol 178:1030-1038. http://dx.doi.org/10.4049/jimmunol.178.2.1030.
13. Dormitzer PR, Galli G, Castellino F, Golding H, Khurana S, Del Giudice G, Rappuoli R. 2011. Influenza vaccine immunology. Immunol Rev 239:167-177. http://dx.doi.org/10.1111/j.1600-065X.2010.00974.x.
14. + T cells induce innate responses independently of pathogen. Nat Med 16:5585644. http://dx.doi.org/10.1038/nm.2142.
15. Brown DM, Dilzer AM, Meents DL, Swain SL. 2006. CD4 T cellmediated protection from lethal influenza: perforin and antibodymediated mechanisms give a one-two punch. J Immunol 177:2888-2898. http://dx.doi.org/10.4049/jimmunol.177.5.2888.
16. Hemann EA, Kang S-M, Legge KL. 2013. Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza viruslike particle vaccination. J Immunol 191:2486-2494. http://dx.doi.org/10.4049/jimmunol.1300954.
17. + T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity. PLoS Pathog 9:e1003207. http://dx.doi.org/10.1371/journal.ppat.1003207.
18. Sambhara S, Kurichh A, Miranda R, Tumpey T, Rowe T, Renshaw M, Arpino R, Tamane A, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D. 2001. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 211:143-153. http://dx.doi.org/10.1006/cimm.2001.1835.
19. Gao W, SoloffAC, Lu X, Montecalvo A, Nguyen DC, Matsuoka Y, Robbins PD, Swayne DE, Donis RO, Katz JM, Barratt-Boyes SM, Gambotto A. 2006. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 80:1959-1964. http://dx.doi.org/10.1128/JVI.80.4.1959-1964.2006.
20. Hessel A, Schwendinger M, Fritz D, Coulibaly S, Holzer GW, Sabarth N, Kistner O, Wodal W, Kerschbaum A, Savidis-Dacho H, Crowe BA, Kreil TR, Barrett PN, Falkner FG. 2010. A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations. PLoS One 5:e12217. http://dx.doi.org/10.1371/journal.pone.0012217.
21. Schultz-Cherry S, Dybing JK, Davis NL, Williamson C, Suarez DL, Johnston R, Perdue ML. 2000. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology 278:55-59. http://dx.doi.org/10.1006/viro.2000.0635.
22. Kopecky-Bromberg SA, Palese P. 2009. Vaccines for pandemic influenza, p 243-267. In Recombinant vectors as influenza vaccines. Springer, New York, NY.
23. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745-1749. http://dx.doi.org/10.1126/science.8456302.
24. Rao SS, Kong W-P, Wei C-J, Van Hoeven N, Gorres JP, Nason M, Andersen H, Tumpey TM, Nabel GJ. 2010. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS One 5:e9812. http://dx.doi.org/10.1371/journal.pone.0009812.
25. Kodihalli S, Haynes JR, Robinson HL, Webster RG. 1997. Crossprotection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin. J Virol 71:3391-3396.
26. Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Matsuo K, Kurata T, Tamura S. 2000. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 18:3214-3222. http://dx.doi.org/10.1016/S0264-410X(00)00149-3.
27. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, Subbarao K, Renshaw M, Sambhara S, Katz JM. 2002. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 8:796-801. http://dx.doi.org/10.3201/eid0805.010476.
28. Quan F-S, Huang C, Compans RW, Kang S-M. 2007. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 81:3514-3524. http://dx.doi.org/10.1128/JVI.02052-06.
29. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM. 2007. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25:3871-3878. http://dx.doi.org/10.1016/j.vaccine.2007.01.106.
30. Galarza JM, Latham T, Cupo A. 2005. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 18:365-372. http://dx.doi.org/10.1089/vim.2005.18.365.
31. Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM. 2008. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26:5393-5399. http://dx.doi.org/10.1016/j.vaccine.2008.07.084.
32. Liu YV, Massare MJ, Pearce MB, Sun X, Belser JA, Maines TR, Creager HM, Glenn GM, Pushko P, Smith GE, Tumpey TM. 2015. Recombinant virus-like particles elicit protective immunity against avian influenza A (H7N9) virus infection in ferrets. Vaccine 33:2152-2158. http://dx.doi.org/10.1016/j.vaccine.2015.03.009.
33. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. 2005. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23:5751-5759. http://dx.doi.org/10.1016/j.vaccine.2005.07.098.
34. Kang SM, Yoo DG, Kim MC, Song JM, Park MK, OE, Quan FS, Akira S, Compans RW. 2011. MyD88 plays an essential role in inducing B cells capable of differentiating into antibody-secreting cells after vaccination. J Virol 85:11391-11400. http://dx.doi.org/10.1128/JVI.00080-11.
35. Lee YT, Ko EJ, Kim KH, Lee YN, Song JM, Kwon YM, Kim MC, Perez DR, Kang SM. 2014. Roles of major histocompatibility complex class II in inducing protective immune responses to influenza vaccination. J Virol 88:7764-7775. http://dx.doi.org/10.1128/JVI.00748-14.
36. Thompson CM, Petiot E, Mullick A, Aucoin MG, Henry O, Kamen AA. 2015. Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems. BMC Biotechnol 15:31. http://dx.doi.org/10.1186/s12896-015-0152-x.
37. Yan J, Villarreal DO, Racine T, Chu JS, Walters JN, Morrow MP, Khan AS, Sardesai NY, Kim JJ, Kobinger GP, Weiner DB. 2014. Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. Vaccine 32:2833-2842. http://dx.doi.org/10.1016/j.vaccine.2014.02.038.
38. Shen X, Soderholm J, Lin F, Kobinger G, Bello A, Gregg DA, Broderick KE, Sardesai NY. 2012. Influenza A vaccines using linear expression cassettes delivered via electroporation afford full protection against challenge in a mouse model. Vaccine 30:6946-6954. http://dx.doi.org/10.1016/j.vaccine.2012.02.071.
39. Grunwald T, Ulbert S. 2015. Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine platforms for the battle against infectious diseases. Clin Exp Vaccine Res 4:1-10. http://dx.doi.org/10.7774/cevr.2015.4.1.1.
40. Zimmer G. 2010. RNA replicons: a new approach for influenza virus immunoprophylaxis. Viruses 2:413-434. http://dx.doi.org/10.3390/v2020413.
41. Halbherr SJ, BrostoffT, Tippenhauer M, Locher S, Berger Rentsch M, Zimmer G. 2013. Vaccination with recombinant RNA replicon particles protects chickens from H5N1 highly pathogenic avian influenza virus. PLoS One 8:e66059. http://dx.doi.org/10.1371/journal.pone.0066059.
42. Uematsu Y, Vajdy M, Lian Y, Perri S, Greer CE, Legg HS, Galli G, Saletti G, Otten GR, Rappuoli R, Barnett SW, Polo JM. 2012. Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity. Clin Vaccine Immunol 19:991-998. http://dx.doi.org/10.1128/CVI.00031-12.
43. Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A. 2013. Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect 2:e52. http://dx.doi.org/10.1038/emi.2013.54.
44. Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen K-J, Stitz L, Kramps T. 2012. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30:1210-1216. http://dx.doi.org/10.1038/nbt.2436.
45. Deering RP, Kommareddy S, Ulmer JB, Brito LA, Geall AJ. 2014. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin Drug Deliv 11:885-899. http://dx.doi.org/10.1517/17425247.2014.901308.
46. Martinez-Gil L, GoffPH, Hai R, Garcia-Sastre A, Shaw ML, Palese P. 2013. A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J Virol 87:1290-1300. http://dx.doi.org/10.1128/JVI.02338-12.
47. Jin B, Sun T, Yu X-H, Liu C-Q, Yang Y-X, Lu P, Fu S-F, Qiu H-B, Yeo AE. 2010. Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant. Biomed Res Int 2010:1-17.
48. Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, O'Hagan DT, Singh M, Mason PW, Valiante NM, Dormitzer PR, Barnett SW, Rappuoli R, Ulmer JB, Mandl CW. 2012. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A 109:14604-14609. http://dx.doi.org/10.1073/pnas.1209367109.
49. Pollard C, Rejman J, De Haes W, Verrier B, Van Gulck E, Naessens T, De Smedt S, Bogaert P, Grooten J, Vanham G, De Koker S. 2013. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther 21:251-259. http://dx.doi.org/10.1038/mt.2012.202.
50. Bogers WM, Oostermeijer H, Mooij P, Koopman G, Verschoor EJ, Davis D, Ulmer JB, Brito LA, Cu Y, Banerjee K, Otten GR, Burke B, Dey A, Heeney JL, Shen X, Tomaras GD, Labranche C, Montefiori DC, Liao H-X, Haynes B, Geall AJ, Barnett SW. 2014. Potent immune responses in rhesus macaques induced by nonviral delivery of a selfamplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J Infect Dis 211:947-955.
51. Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, Scheel B, Voss S, Kallen KJ, Fotin-Mleczek M. 2015. A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. Int J Cancer 137:372-384. http://dx.doi.org/10.1002/ijc.29402.
52. Brito LA, Chan M, Shaw CA, Hekele A, Carsillo T, Schaefer M, Archer J, Seubert A, Otten GR, Beard CW, Dey AK, Lilja A, Valiante NM, Mason PW, Mandl CW, Barnett SW, Dormitzer PR, Ulmer JB, Singh M, O'Hagan DT, Geall AJ. 2014. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther 21:2018-2029.
53. Gallorini S, Taccone M, Bonci A, Nardelli F, Casini D, Bonificio A, Kommareddy S, Bertholet S, O'Hagan DT, Baudner BC. 2014. Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses. Vaccine 32:2382-2388. http://dx.doi.org/10.1016/j.vaccine.2013.12.043.
54. Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3:1101-1108. http://dx.doi.org/10.1038/nprot.2008.73.
55. Smith H, Sweet C. 1988. Lessons for human influenza from pathogenicity studies with ferrets. Rev Infect Dis 10:56-75. http://dx.doi.org/10.1093/clinids/10.1.56.
56. Rowe T, León AJ, Crevar CJ, Carter DM, Xu L, Ran L, Fang Y, Cameron CM, Cameron MJ, Banner D, Ng DCK, Ran R, Weirback HK, Wiley CA, Kelvin DJ, Ross TM. 2010. Modeling host responses in ferrets during A/California/07/2009 influenza infection. Virology 401:257-265. http://dx.doi.org/10.1016/j.virol.2010.02.020.
57. Suzuki R, Winkelmann ER, Mason PW. 2009. Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2. J Virol 83:1870-1880. http://dx.doi.org/10.1128/JVI.01891-08.
58. Middleton D, Rockman S, Pearse M, Barr I, Lowther S, Klippel J, Ryan D, Brown L. 2009. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J Virol 83:7770-7778. http://dx.doi.org/10.1128/JVI.00241-09.
59. Lalor PA, Webby RJ, Morrow J, Rusalov D, Kaslow DC, Rolland A, Smith LR. 2008. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 197:1643-1652. http://dx.doi.org/10.1086/588431.
60. Rockman S, Middleton DJ, Pearse MJ, Barr IG, Lowther S, Brown LE. 2012. Control of pandemic (H1N1) 2009 influenza virus infection of ferret lungs by non-adjuvant-containing pandemic and seasonal vaccines. Vaccine 30:3618-3623. http://dx.doi.org/10.1016/j.vaccine.2012.03.043.
61. van den Brand JMA, Kreijtz JHCM, Bodewes R, Stittelaar KJ, van Amerongen G, Kuiken T, Simon J, Fouchier RAM, Del Giudice G, Rappuoli R, Rimmelzwaan GF, Osterhaus ADME. 2011. Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. J Virol 85:2851-2858. http://dx.doi.org/10.1128/JVI.01939-10.
62. Wei C-J, Boyington JC, McTamney PM, Kong W-P, Pearce MB, Xu L, Andersen H, Rao S, Tumpey TM, Yang Z-Y, Nabel GJ. 2010. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329:1060-1064. http://dx.doi.org/10.1126/science.1192517.
63. Kim Y-C, Yoo D-G, Compans RW, Kang S-M, Prausnitz MR. 2013. Cross-protection by coimmunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. J Control Release 172:579-588. http://dx.doi.org/10.1016/j.jconrel.2013.04.016.
64. Khurana S, Wu J, Dimitrova M, King LR, Manischewitz J, Graham BS, Ledgerwood JE, Golding H. 2013. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J Infect Dis 208:413-417. http://dx.doi.org/10.1093/infdis/jit178.
65. Lin S-C, Liu W-C, Lin Y-F, Huang Y-H, Liu J-H, Wu S-C. 2013. Heterologous prime-boost immunization regimens using adenovirus vector and virus-like particles induce broadly neutralizing antibodies against H5N1 avian influenza viruses. Biotechnol J 8:1315-1322. http://dx.doi.org/10.1002/biot.201300116.
66. Luke CJ, Subbarao K. 2014. Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms. Expert Rev Vaccines 13: 873-883. http://dx.doi.org/10.1586/14760584.2014.922416.
67. Kreijtz JHCM, Bodewes R, van Amerongen G, Kuiken T, Fouchier RAM, Osterhaus ADME, Rimmelzwaan GF. 2007. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25:612-620. http://dx.doi.org/10.1016/j.vaccine.2006.08.036.
68. O'Neill E, Krauss SL, Riberdy JM, Webster RG, Woodland DL. 2000. Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J Gen Virol 81:2689-2696. http://dx.doi.org/10.1099/0022-1317-81-11-2689.
69. Laurie KL, Carolan LA, Middleton D, Lowther S, Kelso A, Barr IG. 2010. Multiple infections with seasonal influenza A virus induce crossprotective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis 202:1011-1020. http://dx.doi.org/10.1086/656188.
70. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, Malzone C, Castellino F, Gentile C, McNally T. 2009. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A 106:7962-7967. http://dx.doi.org/10.1073/pnas.0903181106.
71. Greenbaum JA, Kotturi MF, Kim Y, OseroffC, Vaughan K, Salimi N, Vita R, Ponomarenko J, Scheuermann RH, Sette A, Peters B. 2009. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 106:20365-20370. http://dx.doi.org/10.1073/pnas.0911580106.
72. Kamperschroer C, Swain SL, Grussenmeyer T, Lefkovits I. 2006. SAP deficiency results in a striking alteration of the protein profile in activated CD4 T cells. J Proteome Res 5:1785-1791. http://dx.doi.org/10.1021/pr0600778.
73. Kalams SA, Walker BD. 1998. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188:2199-2204. http://dx.doi.org/10.1084/jem.188.12.2199.
74. + T cells after acute infection. Nat Immunol 5:927-933. http://dx.doi.org/10.1038/ni1105.
75. + T cells protect against influenza through multiple synergizing mechanisms. J Clin Invest 122:2847-2856. http://dx.doi.org/10.1172/JCI63689.
76. + T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. J Exp Med 180:1273-1282. http://dx.doi.org/10.1084/jem.180.4.1273.
77. + T cells correlate with disease protection against influenza challenge in humans. Nat Med 18:274-280. http://dx.doi.org/10.1038/nm.2612.
78. + T-cell expansion predicts neutralizing antibody responses to monovalent, inactivated 2009 pandemic influenza A(H1N1) virus subtype H1N1 vaccine. J Infect Dis 207:297-305. http://dx.doi.org/10.1093/infdis/jis684.
79. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC. 2006. T cell responses are better corre-lates of vaccine protection in the elderly. J Immunol 176:6333-6339. http://dx.doi.org/10.4049/jimmunol.176.10.6333.
80. McKinstry KK, Strutt TM, Swain SL. 2011. Hallmarks of CD4 T cell immunity against influenza. J Intern Med 269:507-518. http://dx.doi.org/10.1111/j.1365-2796.2011.02367.x.
81. + T cells play a prominent role in recall responses to secondary viral infection in the lung. J Immunol 172:6533-6537. http://dx.doi.org/10.4049/jimmunol.172.11.6533.
82. Sambhara S, Woods S, Arpino R, Kurichh A, Tamane A, Underdown B, Klein M, Lövgren Bengtsson K, Morein B, Burt D. 1998. Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes. J Infect Dis 177:1266-1274. http://dx.doi.org/10.1086/515285.